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ABSTRACT 
Introduction 
Significant discrepancies between in vitro and in vivo binding of the muscarinic 
receptor ligand - 3H-labeled Quinuclidinyl Benzylate (QNB) - have been well 
documented. Discernable in vivo cerebellar [3H]QNB binding has been observed in 
mouse brain, despite the maximum number of binding sites (Bmax) being low. In order 
to understand this unique in vivo binding phenomenon, the binding of two muscarinic 
receptor ligands -[3H]QNB and N-[11C]methylpiperidyl Benzylate ([11C]NMPB) - were 
compared in vivo and in vitro in 3- and 8-week-old mice. 
Method 
In vitro binding parameters of [3H]QNB were determined using brain homogenates. The 
time course of radioactivity concentration (TACs) in the cerebral cortex and cerebellum 
were measured following injection of [3H]QNB and [11C]NMPB with or without 3 mg/kg 
of carrier QNB in 3- and 8 week old mice using a dual tracer administration technique. 
A graphical method was employed for the quantitative analysis of in vivo binding of 
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these radioligands.  
Results  
In vitro, the available number of binding sites for cerebral cortical muscarinic receptors 
increased by 17% during the developmental period studied. Paradoxically, in vivo, we 
observed a decrease of [3H]QNB binding in the cerebral cortex, whilst [11C]NMPB 
binding was markedly increased. In vivo saturation analysis of [3H]QNB in 3-week-old 
mice revealed an apparent positive cooperativity of binding in the cerebral cortex. 
Conclusions 
Our results support the hypothesis that microenvironmental factors proximal to 
muscarinic receptors cause a local decrease in the cortical free-ligand concentration of 
[3H]QNB and that this ‘ligand barrier’ is modulated during brain development. 
Advances in Knowledge  
The present study demonstrates that the combined use of radiolabeled QNB and NMPB 
has the potential to reveal the important effects of receptor microenvironmental factors 
on receptor function in the living brain. 
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1. Introduction 
Muscarinic receptors play essential roles in both the central nervous system (CNS) 
[1-3] and peripheral tissues [4, 5]. They have been pharmacologically classified into 
three subclasses: M1, M2, and M3 [6]. M1 receptors are predominantly expressed in the 
striatum, cerebral cortex, and hippocampus, while M2 receptors are mainly distributed 
in the cerebellum and heart [7, 8].  
In vitro binding studies of muscarinic receptors have employed labeled 
Quinuclidinyl Benzylate (QNB) and N-methylpiperidyl Benzylate (NMPB) as 
non-selective radioligands [9-16]. NMPB’s in vivo binding mirrors its known in vitro 
distribution with characteristically low specific binding in the cerebellum, both in vivo 
and in vitro [16,18]. However, a conflicting in vivo cf. in vitro binding profile has been 
reported for [3H]QNB in the intact brain [17, 18]: the specific binding of [3H]QNB in the 
cerebellum of living mice or rats is considerably higher than that measured in vitro. In 
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addition, in vivo saturation experiments on [3H]QNB binding show non-linear (positive 
cooperativity) binding in the cortex and linear saturable binding in the cerebellum [18] 
The aim of the study was to measure changes in binding parameters of [3H]QNB and 
[11C]NMPB during the CNS development process. 3 week old mice were selected as the 
juvenile group, purely on the basis of practicalilities of i.v. cannulation. Mice bellow 3 
weeks of age were excluded because of the size of veins and difficulties in performing i.v. 
injections in these smaller animals. Eight weeks old mice were chosen as adult group. 
As the in vivo dissociation rate of [3H]QNB in the brain (0-60 min) is negligible, specific 
binding is dependent upon the forward-rate constant k3. The k3 includes three 
components: free ligand concentration [F], the bimolecular rate constant (kon) and 
available binding sites (Bmax). In vivo saturation experiments have shown that Bmax 
in the cerebellum is 15-fold lower than that in the cerebral cortex [18]. However, the 
present study observed a significant, unexpected decrease in the in vivo binding of 
[3H]QNB in the cerebral cortex during the 3-8 week development period. 
We speculate that the ligand-concentration dependent modulation of the free 
ligand concentration proximal to the receptors in the cerebral cortex is due to a diffusion 
boundary – a concept initially introduced by Perry et al. [19]. Several lines of evidence 
strongly indicate that membrane fluidity and lipid components in membranes modulate 
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receptor binding and receptor function [20-25]. To the best of our knowledge, this study 
is the first to provide evidence for a modulatory role of the diffusion boundary upon 
receptor function in the developing brain. 
 
2. Materials and methods 
2.1. Labeled compounds and chemicals 
(R)-[3H]QNB (molar activity: 1.44 GBq/µmol) was provided by New England 
Nuclear Research Product. (R)-QNB was provided by Research Biochemicals 
International.  [11C]NMPB (molar activity: 55.5 GBq/µmol) was synthesized using 
[11C]methyl iodide according to a previously reported method [26]. (-)-Scopolamine 
hydrochloride was obtained from Sigma-Aldrich. 
 
2.2. Animals  
Male ddY mice were provided by Japan SLC and housed under a 12－hour light 
cycle with free access to food and water. All animal experiments were approved by the 
Experimental Animal Committee of the National Institute of Radiological Sciences 
(Chiba, Japan). 
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2.3. In vitro homogenate [3H]QNB binding of the cerebral cortex and cerebellum of 3- 
and 8-weeks-old mice 
Mice (3 and 8 weeks old; the body weights were 12 g and 33 g, respectively) were 
decapitated under diethyl ether anesthesia, and their brains were rapidly removed. 
Homogenates of the cerebral cortex and cerebellum were prepared as 0.05 M Na-K 
phosphate buffer solutions (1 mg/mL: cerebral cortex; 2 or 5 mg/mL: cerebellum). 
[3H]QNB was dissolved in 0.05 M Na-K phosphate buffer solution (from 100 pM to 2000 
pM). Each homogenate solution was incubated with 1 mL of [3H]QNB at 37°C for 30 
minutes. After incubation, the B/F separation was made using glass filters (Whatmann, 
CF/C Filter). The incubation tubes were washed twice with ice-cold buffer, and the glass 
filters were washed five times with ice-cold water. The filters were transferred into 
scintillation vials, and 10 mL of liquid scintillator (Packard, Hionic Flow) was added. 
Radioactivity in each vial was determined by a liquid-scintillation counter (Aloka, 
LSC-5100), and the non-specific binding (NSB) was determined using 1 µM of 
scopolamine. The specific binding was determined by subtraction of NSB from total 
radioactivity in each ligand concentration. The estimation of KD and Bmax values was 
performed by using the Scachard Plot. 
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2.4. Dual tracer protocol 
[3H]QNB (0.2 mL; 74 KBq) and [11C]NMPB (0.2 mL; 3.5MBq) were intravenously 
injected into 3- and 8-week-old mice, which were subsequently decapitated under 
diethyl ether at 1, 5, 10, 20, 30, 45, and 60 minutes post-injection. The brains were 
quickly removed, and dissected into the cerebral cortex and cerebellum. After weighing 
the specimens, the radioactivity of 11C of each sample was measured via a gamma 
well-counter (Packard 5230). After the decay of 11C was determined, each sample was 
dissolved using a tissue solubilizer (Packard; Soluene 350). The radioactivity of each 
sample was determined by a liquid scintillation counter (Beckman; LS6800).  
The in vivo time course of radioactivity concentration (TAC) was determined in the 
plasma and brains of 3- and 8-week-old mice. Non-specific binding (NSB) was 
ascertained by measuring the TAC in each region following the intravenous injection of 
[3H]QNB and [11C]NMPB together with 3 mg/kg of the carrier QNB. 
 
2.5. Kinetic analysis of in vivo [3H]QNB and [11C]NMPB binding in the cerebral cortex 
and cerebellum 
The graphical method (the Patlak plot) [27] was employed for the quantitative 
analysis of in vivo [3H]QNB and [11C]NMPB binding in the cerebral cortex and 
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cerebellum. The TACs of [3H]QNB or [11C]NMPB with 3 mg/kg of carrier QNB in the 
cerebellum were used to estimate the free-ligand concentration in the brain and as 
input functions for the kinetic analysis. The binding parameter, k3, of [3H]QNB and 
[11C]NMPB in the cerebral cortex and cerebellum of 3-and 8-weeks-old mice were 
estimated. 
 
2.6. In vivo saturation study of [3H]QNB binding in the cerebral cortex and cerebellum 
of 3-weeks old mice 
Mice (n = 3) were intravenously injected with [3H]QNB together with different 
doses of non-radioactive QNB, ranging from 3 µg/kg to 3000 µg/kg, and were sacrificed 
by decapitation under ethyl ether anesthesia 60 min after the injection. Radioactivity in 
the cerebral cortex and cerebellum was measured as described above. Specific binding 
was calculated by subtracting the radioactivity concentration in the cerebellum 
(co-injected with 3000 µg/kg of [3H]QNB) from the corresponding radioactivity 
concentration in each region. 
2.7. Statistical analysis 
Student’s-t test was used for the statistical analysis. 
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3. Results 
The results of the in vitro binding in the cerebral cortex and cerebellum in 3- and 
8-weeks-old mice are shown in Table 1. In the cerebral cortex, [3H]QNB bound to a 
single binding site. Bmax in the cerebral cortex increased during the development 
period with no significant changes in affinity. In the cerebellum, no significant 
difference of binding parameters were observed. 
The time course of [3H]QNB and [11C]NMPB radioactivity concentrations (TAC) in 
the cerebral cortex and cerebellum of 3-weeks-old mice (with or without the 3 mg/kg of 
carrier), are summarized in Tables 2, and 3. TACs for 8-week-old mice are shown in 
Tables 4 and 5. In 3-week-old mice, radioactivity was highly retained in the brain when 
[3H]QNB was injected at tracer doses. However, when [3H]QNB was injected together 
with the 3 mg/kg of the carrier, radioactivity concentrations in the brain decreased 
rapidly over time. A similar result was found in 8-week-old mice. The TACs for 
[11C]NMPB binding in 3- and 8-week-old mice, with or without carrier QNB, are shown 
in Tables 3 and 5. When [11C]NMPB was injected at tracer levels, higher radioactivity 
concentrations were observed in the cerebral cortex of both 3- and 8-week-old mice 
relative to radioactivity concentrations of [3H]QNB. When the 3 mg/kg of carrier QNB 
was injected together with [11C]NMPB, a rapid tracer washout was observed in the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
brains of 3- and 8-week-old mice. The Patlak plots for [3H]QNB and [11C]NMPB binding 
in the cerebral cortex and cerebellum of 3- and 8-weeks-old mice are shown in Figures 1 
and 2. Linear slopes were observed for both [3H]QNB and [11C]NMPB binding in the 
cerebral cortex of 3- and 8-weeks-old mice. The slope of the straight line for [3H]QNB 
binding in 8-week-old mice was significantly shallower than that in 3-weeks-old mice, 
whereas that of [11C]NMPB in the cerebral cortex of 8-week-old mice was steeper than 
that in 3-weeks-old mice. In the cerebellum, no significant difference in the slope of the 
line for [3H]QNB was observed between 3- and 8-week-old mice. The estimated k3 values 
for [11C]NMPB and [3H]QNB binding in the cerebral cortex and cerebellum are shown in 
Figures 1 and 2. 
The results of the in vivo [3H]QNB saturation experiments in 3-week-old mice are 
shown in Table 6 and Figure 3. Positive cooperativity of in vivo binding in the cerebral 
cortex was observed, while a simple competitive inhibition was found in the cerebellum. 
 
4. Discussion  
The in vitro Bmax of muscarinic receptors in the cerebral cortex significantly 
increased during the CNS development process, while the affinity of [3H]QNB remained 
unchanged. In the cerebellum, no significant changes in the binding parameters were 
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seen. The M1 subtype of the muscarinic receptors is known to be highly expressed in the 
cerebral cortex and striatum, while M2 receptors appear to be the predominant subtype 
expressed in the cerebellum and heart [7, 8]. Our in vitro binding data therefore 
suggests that the M1-receptor expression in the cerebral cortex increases over the 3 to 8 
weeks period of development. These data are consistent with those of a previous report, 
which found that, in vitro, the amount of QNB bound per mg membrane protein 
increased in whole-mouse-brain preparations from 14 to 42 days of age with no change 
in ligand affinity [28]. 
The most important finding of this study is that the in vivo binding of [3H]QNB in 
the cerebral cortex of 8-week-old mice significantly decreases relative to that of 
3-week-old mice, despite an increase in Bmax exhibited by the older mice. The kinetic 
analysis performed with the Patlak plot showed a significant reduction in [3H]QNB 
binding (k3) in the cerebral cortex from 3 to 8 weeks of age (Figure 1). However, a 
remarkable increase in [11C]NMPB binding in this region was observed in 8-weeks-old 
mice. As shown in Figures 1 and 2, the slope of [3H]QNB binding in the cerebral cortex 
of 8-week-old mice was less than 20% of that of the 3-week-old mice, while the slope for 
[11C]NMPB binding in this region was increased in 8-week-old mice relative to the 
3-week-old mice. On the other hand, the gradient of the slope for [3H]QNB binding in 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
the cerebellum was not significantly different during the development period studied. 
The slope of the regression line, in this case, reflects k3 of a two-compartment model and 
includes [F], kon, and Bmax. As previously reported, the in vivo binding of [11C]NMPB 
parallels the distribution of muscarinic receptors in the brain, which suggested that 
NMPB was a non-subtype selective ligand both in vitro and in vivo.[16, 18]. Therefore, 
an increase in the binding potential of [11C]NMPB in 8-week-old mice may relate to an 
increase in the Bmax in the developing brain. A significant decrease in cerebral cortical 
[3H]QNB binding during the studied development period was an unexpected finding. 
Since the Bmax in the cerebral cortex was higher in 8-week-old mice, the reduction of 
the Patlak slope can be attributed to a decrease in either [F] or kon in the cerebral 
cortex. A difference in the radiotracer delivery from the plasma to the brain seems 
unlikely, because the TACs in the cerebral cortex good BBB permeability for both 
radioligands under carrier added conditions. Thus, the current observations may be 
accounted for by a decrease of either [F] or kon for [3H]QNB in the cerebral cortex in the 
developing brain. [3H]QNB was well known non subtype selective ligand with high 
affinity( KD: 136 pM for rat cerebral and cerebellar synaptosomes)[29]. It has been well 
documented that Gilter et al. proposed that [3H]QNB is an M2 selective ligand under in 
vivo conditions [17, 32], despite its being a non-subtype selective radioligand in vitro 
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[29]. Although the hypothesis that high accumulation of [3H]QNB in the cerebellum 
(M2-subtype rich region) could be due to differences in the in vivo and in vitro 
subtype-selectivity of [3H]-QNB, further evidence is required to test this possible 
explaination. Several brain permeable subtype-selective ligands are currently available. 
Bakker et al developed 123I-iododexetimide as a M1 selective SPECT ligand [30]. 
[18F]FP-TZTPI was evaluated as a M2 selective PET probe in subtype knockout mouse 
[31]. These subtype-selective ligands might be of value to verify the validity of the above 
hypothesis. The latter hypothesis, however, is not able to explain the current 
observation that in vivo binding of [3H]QNB in the cerebral cortex is decreased during 
the development period, since the cerebral cortex is an M1-subtype rich region [7], The 
reason for selective changes in the kon of [3H]QNB in the cerebral cortex during 
development is thus far unexplained. We, however, postulate that significant reductions 
in the free-ligand concentration surrounding the muscarinic receptor itself occur during 
the 3 to 8 weeks development period in mice. It is speculated that diffusion barriers 
cause this effect and that the heterogeneity of the microenvironment surrounding 
receptors plays a critical role in modulating effective free-ligand concentrations in vivo. 
Perry et al. introduced the concept of the diffusion boundary to explain the long-term 
retention of opioid antagonists in the intact brain [19]: the model posits that the 
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receptor micro-compartment consists of a population of binding sites next to a diffusion 
boundary, which restricts ligand diffusion away from the receptor. Interestingly, this 
diffusion boundary phenomenon disappears when brain tissue is homogenized [33], 
suggesting that the diffusion boundary may only be manifest in vivo. We expand the 
concept of the diffusion boundary by suggesting that the free-ligand concentration in a 
micro-compartment might be altered by microenvironments surrounding the receptors. 
These unknown barriers for [3H]QNB binding either increase or change during the 3 to 
8 week development process, although it is unclear whether such barriers are related to 
the interfacial effect we have previously proposed [34]. Providing further support for our 
hypothesis, the present experiment on in vivo [3H]QNB binding in the brains of 
3-week-old mice revealed positive cooperativity of binding in the cerebral cortex but not 
in the cerebellum (Figure 3). 
Several lines of evidence indicate that alterations in membrane fluidity (and lipid 
membrane composition) affect receptor binding and function in the CNS [20-25]. 
Inactivation of muscarinic receptors in synaptic membranes by free fatty acids has been 
reported [20]. Dietary choline intake significantly increases the in vivo binding of 
[3H]Ro15-1788 in all regions of the mouse brain [21]. Changes in striatal dopamine and 
acetylcholine receptors are induced by the chronic administration of cytidine 
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5’-diphosphocholine to aged mice [22]. The affinity of muscarinic receptors to 
antagonists is modulated by the lipid environment [23]. Lipid peroxidation causes 
changes in membrane fluidity as well as muscarinic receptor binding in the rat cerebral 
cortex [24]. In addition, lipid fluidity modulates the binding of serotonin to mouse brain 
membranes [25]. Taken together, these reports strongly suggest that lipid composition 
plays an essential role in ligand-receptor interactions, both in vitro and in vivo. To the 
best of our knowledge, there are no reports concerning the changes in lipid composition 
in the developing brain. Such alterations in lipid composition in the brain may, however, 
relate to changes in the diffusion barrier, the existence of which is supported by our 
measurements of [3H]QNB binding in the cerebral cortex. 
The reason for a barrier in the cerebral cortex and not in the cerebellum is 
unknown: however, it may be related to the high density of muscarinic receptors in this 
region. In fact, in vivo binding of [3H]QNB in other receptor-rich areas, such as the 
striatum, also decreases at 8 weeks of age (data not shown).  
The present study found that in vivo [3H]QNB binding in the cerebral cortex was 
significantly decreased in 8-week-old vs. 3-week-old mice, despite an increase in Bmax 
during development. We previously reported an increase of in vivo binding of [3H]QNB 
in the left striatum of rat brain infused with ibotenic acid 14 days prior to the tracer 
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experiment. On the other hand, in vitro autoradiograms showed significant decreases in 
[3H]QNB binding in serial slices in the same rat due to decrease in number of binding 
sites [35]. These findings support our hypothesis, because neural cell death induced by 
ibotenic acid would alter the microenvironment surrounding muscarinic receptors 
resulting in a loss of the barrier effect. Further research is required to elucidate the 
reasons underlying this paradox as well as the observed discrepancies between the in 
vivo binding of [3H]QNB and [11C]NMPB. However, our research has demonstrated that 
the combined use of these radioligands is valuable for examining the physiological and 
pharmacological roles of barrier-modulation in the developing brain.  
 
5. Conclusion  
A significant discrepancy between the in vivo binding of [3H]QNB and [11C]NMPB 
was observed in the cerebral cortex of mice during the 3 to 8 week period of development. 
Increased [11C]NMPB binding is most likely due to an increase in Bmax. On the other 
hand, in vivo binding of [3H]QNB in 8-week-old mice was significantly decreased 
relative to that exhibited by their 3-weeks-old counterparts. Though the reason for the 
discrepancy between the in vivo binding of [3H]QNB and [11C]NMPB remains unclear, 
we hypothesize that a heightened barrier-effect in the developing brain accounts for 
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these contradictory observations. Future studies on the effect of membrane lipid 
components on in vivo binding of [3H]QNB are required. 
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Tables 
Table 1. In vitro binding parameters of [3H]QNB in the cerebral cortex of 3- and 
8-week-old mice. Values are represented as mean ± SD of five runs for cereberal cortex 
of 3- and 8-week-old mice, three runs for cerebellum of 3-week-old mice, and four runs 
for cerebellum of 8-week-old mice. * p<0.01; 3-week-old mice vs. 8-week-old mice. 
 Cerebral Cortex Cerebellum 
 Kd Bmax Kd Bmax  
3 weeks 0.110 ± 0.017 0.159 ± 0.015 0.050 ± 0.022 0.019 ± 0.003 
8 weeks 0.102 ± 0.020 0.195 ± 0.018* 0.056 ± 0.022 0.016 ± 0.003 
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Table 2. The time course of radioactivity concentration in the plasma, cerebral cortex, 
and cerebellum following injection of [3H]QNB with (CA) or without (CF) 3 mg/kg of 
carrier QNB into 3-week-old mice. Values are expressed as percent injected dose / gram 
tissue or mean ± SD of the three mice in each group. 
Time (min) Absence of carrier QNB (CF) 
Plasma Cerebral Cortex Cerebellum 
1 2.52 ± 0.14 6.39 ± 0.33 5.85 ± 0.53 
5 4.05 ± 0.19 10.0 ± 1.1 7.82 ± 0.45 
10 5.14 ± 0.45 12.8 ± 0.3 8.46 ± 0.41 
20 5.19 ± 0.37 14.2 ± 0.5 8.53 ± 0.86 
30 4.73 ± 0.25 14.9 ± 0.8 8.55 ± 0.61 
45 3.47 ± 0.05 17.1 ± 0.6 9.34 ± 0.25 
60 2.82 ± 0.37 16.7 ± 0.6 8.95 ± 1.15 
 
Time (min) Presence of carrier QNB (CA) 
Plasma Cerebral Cortex Cerebellum 
1 2.36 ± 0.11 6.66 ± 0.73 6.01 ± 0.21 
5 3.48 ± 0.13 8.13 ± 0.31 6.87 ± 0.19 
10 5.18 ± 0.41 6.24 ± 0.25 4.91 ± 0.17 
20 5.74 ± 0.07 4.47 ± 0.26 3.40 ± 0.32 
30 5.10 ± 0.20 2.44 ± 0.25 1.67 ± 0.15 
45 3.76 ± 1.11 1.67 ± 0.16 1.19 ± 0.09 
60 2.99 ± 0.37 1.13 ± 0.16 0.79 ± 0.08 
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Table 3. The time courses of radioactivity concentration in the plasma, cerebral cortex, 
and cerebellum following injection of [11C]NMPB with (CA) or without (CF) 3 mg/kg of 
carrier QNB into 3-week-old mice. Values are expressed as percent injected dose / gram 
tissue or mean ± SD of the three mice in each group. 
Time (min) Absence of carrier QNB (CF) 
Plasma Cerebral Cortex Cerebellum 
1 2.54 ± 0.08 15.1 ± 2.0 11.2 ± 1.0 
5 3.39 ± 0.24 21.9 ± 2.6 12.1 ± 0.8 
10 3.63 ± 0.30 25.7 ± 1.7 10.2 ± 1.0 
20 3.52 ± 0.31 24.8 ± 1.6 5.55 ± 0.46 
30 3.36 ± 0.18 24.2 ± 2.1 3.56 ± 0.55 
45 2.46 ± 0.14 22.5 ± 1.9 2.47 ± 0.22 
60 2.31 ± 0.45 20.3 ± 1.5 1.67 ± 0.20 
 
Time  (min) 3mg/kg carrier QNB (CA) 
Plasma Cerebral Cortex Cerebellum 
1 2.41 ± 0.11 13.0 ± 1.5 11.2 ± 0.6 
5 2.64 ± 0.04 14.7 ± 0.1 12.6 ± 0.2 
10 3.20 ± 0.17 11.9 ± 0.4 9.10 ± 0.38 
20 3.52 ± 0.22 7.92 ± 1.79 5.99 ± 1.27 
30 3.71 ± 0.17 3.99 ± 0.16 3.11 ± 0.12 
45 2.85 ± 0.75 2.29 ± 0.39 1.95 ± 0.29 
60 2.46 ± 0.23 1.39 ± 0.17 1.21 ± 0.13 
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Table 4. The time course of radioactivity concentration in the plasma, cerebral cortex, 
and cerebellum following injection of [3H]QNB with (CA) or without (CF) 3 mg/kg of 
carrier QNB into 8-week-old mice. Values are expressed as percent injected dose / gram 
tissue or mean ± SD of the three mice in each group. 
Time (min) Absence of carrier QNB (CF) 
Plasma Cerebral Cortex Cerebellum 
1 1.19 ± 0.07 1.83 ± 0.19 1.51 ± 0.06 
5 1.42 ± 0.26 2.41 ± 0.16 1.87 ± 0.07 
10 1.64 ± 0.03 2.95 ± 0.03 2.11 ± 0.07 
20 1.73 ± 0.11 3.61 ± 0.08 2.49 ± 0.14 
30 1.39 ± 0.02 3.84 ± 0.08 2.58 ± 0.05 
45 1.30 ± 0.13 4.05 ± 0.21 2.81 ± 0.15 
60 0.93 ± 0.11 4.40 ± 0.11 2.83 ± 0.09 
 
Time (min) 3mg/kg carrier QNB (CA) 
Plasma Cerebral Cortex Cerebellum 
1 1.12 ± 0.06 2.51 ± 0.28 2.33 ± 0.16 
5 1.31 ± 0.05 2.36 ± 0.28 2.00 ± 0.27 
10 1.30 ± 0.10 1.83 ± 0.21 1.46 ± 0.18 
20 1.84 ± 0.04 1.44 ± 0.12 0.96 ± 0.07 
30 1.62 ± 0.08 0.91 ± 0.14 0.58 ± 0.11 
45 1.31 ± 0.06 0.60 ± 0.06 0.46 ± 0.04 
60 1.02 ± 0.07 0.51 ± 0.02 0.39 ± 0.03 
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Table 5. The time course of radioactivity concentration in the plasma, cerebral cortex, 
cerebellum, and heart following injection of [11C]NMPB with (CA) or without (CF) 3 
mg/kg of carrier QNB into 8-week-old mice. Values are expressed as percent injected 
dose / gram tissue or mean ± SD of the three mice in each group. 
Time (min) Absence of carrier QNB (CF) 
Plasma Cerebral Cortex Cerebellum 
1 1.30 ± 0.13 6.78 ± 0.34 4.96 ± 0.31 
5 1.24 ± 0.21 9.61 ± 0.51 5.57 ± 0.13 
10 1.40 ± 0.04 11.4 ± 0.5 4.48 ± 0.32 
20 1.42 ± 0.05 13.5 ± 0.2 3.02 ± 0.21 
30 1.05 ± 0.05 13.3 ± 0.2 1.80 ± 0.10 
45 1.07 ± 0.22 13.3 ± 0.9 1.41 ± 0.25 
60 0.73 ± 0.11 13.4 ± 0.9 1.00 ± 0.17 
 
Time (min) 3 mg/kg carrier QNB (CA) 
Plasma Cerebral Cortex Cerebellum 
1 1.15 ± 0.07 5.71 ± 0.60 4.87 ± 0.38 
5 1.11 ± 0.05 5.98 ± 0.78 4.79 ± 0.63 
10 1.23 ± 0.13 4.40 ± 0.53 3.43 ± 0.44 
20 1.41 ± 0.06 2.99 ± 0.31 2.14 ± 0.23 
30 1.28 ± 0.06 1.79 ± 0.25 1.24 ± 0.20 
45 1.05 ± 0.14 0.97 ± 0.11 0.70 ± 0.08 
60 0.80 ± 0.11 0.61 ± 0.04 0.46 ± 0.05 
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Table 6. In vivo saturation of [3H]QNB binding in the cerebral cortex and cerebellum of 
3-week-old mice. Values are expressed as percent injected dose / gram tissue or mean ± 
SD of the three mice in each group. 
Dose (g/kg) * Cerebral Cortex Cerebellum 
0 13.13 ± 1.31 8.45 ± 0.64 
10 12.50 ± 0.73 4.32 ± 0.17 
30 12.39 ± 1.05 2.60 ± 0.28 
100 6.18 ± 0.23 1.87 ± 0.26 
300 3.08 ± 0.20 1.57 ± 0.14 
1000 1.78 ± 0.12 1.37 ± 0.02 
3000 1.28 ± 0.13 1.13 ± 0.13 
*Doses of carrier QNB 
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Legends for Figures 
 
Figure 1  
Patlak plot for the [3H]QNB binding in the cerebral cortex and cerebellum in 3- and 
8-week-old mice. Free-ligand concentrations were assumed to correspond to the 
non-specific binding at each time point. CF: radioactivity concentration in the cerebral 
cortex and cerebellum at each time point after the injection of [3H]QNB into 3- and 
8week old mice. CA: radioactivity concentration in the cerebellum at each time point 
after the injection of [3H]QNB with 3 mg/kg of carrier QNB into 3w or 8 week old mice. 
The average of the ratio of radioactivity concentration (CF/CA) at each time point was 
used. Normalized integral time was calculated as follows; ΣCA/CA. Statistical analysis 
was performed for the slope of regression line for the cerebral cortex and cerebellum 
between 3w and 8 weeks old mice. Sttistical significance (p<0.01) was observed in the 
slope of regression line for the cerebral cortex. 
 
Figure 2 
    Patlak plot for the [11C]NMPB binding in the cerebral cortex and cerebellum in 3- 
and 8-week old mice. Free ligand concentrations were assumed to correspond to the 
non-specific binding at each time point. CF: radioactivity concentration in the cerebral 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
33 
 
cortex and cerebellum at each time point after the injection of [11C]NMPB into 3- and 
8week old mice. CA: radioactivity concentration in the cerebellum at each time point 
after the injection of [11C]NMPB with 3 mg/kg of carrier QNB into 3- and 8 week old 
mice. The average of the ratio of radioactivity concentration (CF/CA) at each time point 
was used. Normalized integral time was calculated as follows; ΣCA/CA. Statistical 
analysis was performed for the slope of regression line for the cerebral cortex and 
cerebellum between 3- and 8 week old mice. Sttistical significance (p<0.01) was 
observed in the slope of regression line for the cerebral cortex. 
  
Figure 3 
      Scatchard plot for in vivo binding of [3H]QNB in the cerebral cortex and 
cerebellum of 3-week-old mice. The specific binding in the cerebellum was assumed to 
be saturated by 300 µg/kg of carrier QNB.  
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